Efficacy and safety of ixekizumab treatment for Japanese patients with moderate to severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis: Results from a 52‐week, open‐label, phase 3 study (UNCOVER‐J)

Psoriasis, a chronic, immune‐mediated skin disease characterized by red, scaly plaques, affects approximately 0.3% of the population in Japan. The aim of this open‐label study was to evaluate the long‐term efficacy and safety of ixekizumab, a humanized, anti‐interleukin‐17A monoclonal antibody, in J...

詳細記述

保存先:
書誌詳細
出版年:J Dermatol
主要な著者: Saeki, Hidehisa, Nakagawa, Hidemi, Nakajo, Ko, Ishii, Taeko, Morisaki, Yoji, Aoki, Takehiro, Cameron, Gregory S., Osuntokun, Olawale O., Akasaka, Toshihide, Asano, Yoshihide, Etoh, Takafumi, Fujita, Yasuyuki, Hashimoto, Takashi, Higashiyama, Mari, Igarashi, Atsuyuki, Ihn, Hironobu, Iwatsuki, Keiji, Kabashima, Kenji, Kawada, Akira, Kawashima, Makoto, Nakamura, Koichiro, Okubo, Yukari, Okuyama, Ryuhei, Ozawa, Akira, Sayama, Koji, Seishima, Mariko, Shiohara, Tetsuo, Takahara, Masakazu, Takahashi, Hidetoshi, Takehara, Kazuhiko, Tanese, Keiji, Tani, Mamori, Umezawa, Yoshinori, Watanabe, Hideaki, Yamanaka, Keiichi
フォーマット: Artigo
言語:Inglês
出版事項: John Wiley and Sons Inc. 2016
主題:
Original Articles
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC5412888/
https://ncbi.nlm.nih.gov/pubmed/27726163
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/1346-8138.13622
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料